Cost-effectiveness of atypical antipsychotics in severely and persistently mentally III patients with schizophrenia and schizoaffective disorders

Drug Benefit Trends

Volumn 13, Issue 2, 2001, Pages

  Karki, S D ^a   Bellnier, T J ^a   Patil, K ^a   Oretega, T ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Antipsychotics; Schizoaffective disorders; Schizophrenia

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG FORMULARY; DRUG PREFERENCE; DRUG SAFETY; FEMALE; HUMAN; MALE; MENTAL DISEASE; POPULATION RESEARCH; PRESCRIPTION; PROSPECTIVE STUDY; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

EID: 0035092170     PISSN: 10805826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Schizophrenia
2. The relationship of pharmacology to side effects
3. Side effects of new antipsychotic agents
4. Relapse and rehospitalization during maintenance treatment of schizophrenia
5. Comparison of withdrawal of typical and atypical antipsychotic drugs: A case study
6. Patient compliance in the mental health continuum of care
7. Psychiatric and social reasons for frequent rehospitalization
8. Identifying modifiable risk factors for rehospitalization: A case control study of seriously mentally ill persons in Mississippi
9. The evaluation and treatment of first-episode psychosis
10. Atypical antipsychotic drugs and long-term outcome in schizophrenia
11. Effects of clozapine on cognitive function in schizophrenia
12. The effects of risperidone vs haloperidol on cognitive functioning in treatment-resistant schizophrenia; The trail making tests
13. Psychomotor impairment and cognitive disturbances induced by neuroleptics
14. Negative priming (cognitive inhibition) in psychiatric patients: Effect of neuroleptics
15. Clozapine eligibility among state hospital patients
16. Reduction in hospital days in chronic schizophrenic patients treated with risperidone: A retrospective study
17. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial
18. Conventional versus atypical neuroleptics: Subjective quality of life in schizophrenic patients
19. Motor and mental aspects of EPS
20. Longitudinal analysis of abnormal movements in long-term clozapine-treated patients
21. Effects of risperidone in tardive dyskinesia: An analysis of the Canadian multicenter risperidone study
22. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol
23. New atypical antipsychotic medications
24. Atypical antipsychotics, I: Pharmacology, pharmacokinetics, and efficacy
25. Atypical antipsychotics, II: Adverse effects, drug interactions, and costs
26. New antipsychotic agents: Emerging clinical profiles
27. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials
28. Treatment of schizophrenia: Let's talk dollars and sense
29. Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia
30. Prescribing risperidone
31. Savings in hospital bed days related to treatment with clozapine
32. Cost-effectiveness of clozapine
33. Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia
34. Impact of risperidone on the use of mental health care resources
35. Intent-to-treat analysis of repeated measured data from a randomized clinical trial comparing the cost and effectiveness of treatment for schizophrenia with olanzapine or haloperidol
36. The Brief Psychiatric Rating Scale
37. Cost-effectiveness analysis
38. Clozapine-induced agranulocytosis, incidence and risk factors in the United States
39. Clozapine for the treatment resistant schizophrenic: A double blind comparison with chlorpromazine
40. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
41. Pharmacoeconomics of antipsychotic drug therapy
42. Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry